查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
非酒精性脂肪性肝炎治疗和诊断全球市场-2022-2029
市场调查报告书
商品编码
1140694

非酒精性脂肪性肝炎治疗和诊断全球市场-2022-2029

Global Non-Alcoholic Steatohepatitis Therapeutics and Diagnostics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场动态

非酒精性脂肪性肝炎生物标誌物研究将在预测期内继续支持市场增长

增加研究活动以提高现有生物标誌物的生产力和效率或发现新的生物标誌物将为非酒精性脂肪性肝炎市场的增长创造重大机遇。预计。非酒精性脂肪性肝炎的患病率在全球范围内急剧增加，从而增加了对各种诊断方法的需求。目前，非酒精性脂肪性肝炎的诊断方法包括活检，这是一种侵入性手术。肝活检仍然是诊断非酒精性脂肪性肝炎的最终标准，但它可能导致各种临床并发症，包括创伤和出血。

政府通过计划和举措提供的支持也促进了全球市场的增长。越来越多的开发非酒精性脂肪性肝炎治疗和诊断工具的计划和举措正在显着推动市场的增长。例如，2021年，全球肝臟研究所公布了美国NASH行动计划。该计划包括关于标准护理和协调护理途径的更新指南、非侵入性诊断的采用和报销、就以患者为中心的基于价值的护理和福利设计、公共卫生、监管和整合 NASH 对支付者和医疗保健系统进行调查。

地理渗透

北美将是预测期内的主要地区

北美在全球非酒精性脂肪性肝炎治疗和诊断市场中占据主导地位，预计在预测期内将保持其地位。在预测期内，美国将占据北美非酒精性脂肪性肝炎治疗和诊断市场的最大份额。市场增长的主要驱动力包括为生物标誌物研发提供大量资金的政府机构和製药公司。此外，先进医疗设施的存在以及糖尿病、肥胖症和脂肪肝疾病患病率的上升也推动了该地区目标市场的增长。

据估计，在预测期内，亚太地区的非酒精性脂肪性肝炎治疗和诊断市场将出现大幅增长。亚太地区的增长主要是由于医疗基础设施的快速发展和对慢性肝病的认识不断提高。此外，外资企业也正在向中国、印度等新兴国家进军。

竞争格局。

非酒精性脂肪性肝炎治疗和诊断市场是一个竞争激烈的市场。为全球市场增长做出贡献的领先非酒精性脂肪性肝炎治疗和诊断製造商包括 Abbvie Inc.、Cadila Healthcare Limited、Genfit SA、Gilead Sciences Inc.、Novo Nordisk A/S、Quest Diagnostics，包括 Shire Plc、Siemens Healthineers 和赛默飞世尔科技公司主要参与者正在为非酒精性脂肪性肝炎治疗和诊断市场的全球增长采用新产品发布和扩张战略。 2020 年 2 月，Meridian Bioscience 签订了收购 exalenz bioscience 的最终协议。两家公司的收购价约为4900万美元。通过此次收购，Meridian 增加了 Exalenz 的旗舰 BreathID 呼吸测试系统，这是一种用于检测幽门螺桿菌的尿素呼吸测试平台，通常与消化性溃疡和胃溃疡癌有关。 BreathID 进一步推进了 Meridian 成为胃肠道诊断解决方案领先供应商的战略。该平台为成人和儿童患者提供对患者友好的非侵入性样本采集和一流的灵敏度和特异性。同样在 2021 年 12 月，赛默飞世尔科技宣布以 174 亿美元收购 PPD，后者是一家为生物製药和生物技术行业提供临床研究服务的全球供应商。 PPD 服务于生物技术和生物製药行业。

COVID-19 对全球非酒精性脂肪性肝炎治疗和诊断市场的负面影响

COVID-19 大流行正在阻碍非酒精性脂肪性肝炎治疗和诊断市场的增长。非酒精性脂肪性肝炎患者患 COVID-19 的风险明显更高，但在危机期间新的诊断和治疗方法正在下降。此外，将 COVID-19 疫苗转用于研发减少了研究机构和其他私人组织正在进行的研究。因此，预计2020年非酒精性脂肪性肝炎治疗和诊断的需求将降低市场价值增长。

全球非酒精性脂肪性肝炎治疗和诊断市场报告提供了大约 76 个市场数据表、60 个图表和 170 页的结构。

内容

第 1 章调查方法及范围

  • 调查方法
  • 市场范围

第 2 章主要趋势和发展

第 3 章执行摘要

  • 按诊断代理划分的市场细分
  • 按药物划分的市场细分
  • 按销售渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 促进因素
    • 抑制因素
    • 商机
  • 影响分析

第 5 章行业分析

  • 波特五力分析
  • 价值链分析
  • 专利分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措

第 7 章诊断

  • 诊断成像技术
  • 诊断测试
  • 活检

第 8 章治疗

  • Ocaliva
  • Elafibranor
  • Senikriviroku
  • Seronsertib
  • 其他

第 9 章按销售渠道

  • 医院药房
  • 在线频道
  • 零售渠道

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 意大利
    • 其他欧洲地区
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 竞争场景
  • 竞争对手战略分析
  • 市场情况/份额分析
  • 併购分析

第 12 章公司简介

  • Abbvie Inc.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • Cadila Healthcare Limited
  • Conatus Pharmaceuticals Inc.
  • Exalenz Bioscience Ltd.
  • Genfit SA
  • Gilead Sciences Inc.
  • Intercept Pharmaceuticals Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Quest Diagnostics
  • Shire Plc
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec

第 13 章 DataM

简介目录
Product Code: DMHCIT2968

Market Overview

Non-alcoholic steatohepatitis therapeutics and diagnostics market was valued USD million in 2021 and is estimated to reach USD million by 2029, growing at a CAGR of 22.31% during the forecast period (2022-2029).

Non-alcoholic steatohepatitis (NASH) is a common cause of chronic liver disease strongly associated with insulin resistance leading to fibrosis. Type 2 diabetes and NAFLD commonly exist together. NAFLD comprises simple steatosis (NAFL), non-alcoholic steatohepatitis, and cirrhosis. According to the National Institute of Health, in 2021, Type 2 diabetes results from the body's ineffective use of insulin. In year 2021 more than 95% of people with diabetes have type 2 diabetes. Hence the rising incidence and prevalence rate of diabetes creates significant scope for the non-alcoholic steatohepatitis therapeutics and diagnostics market. The rising prevalence of non-alcoholic steatohepatitis and the high prevalence of liver-related diseases are some factors that are expected to propel market growth.

Market Dynamics: Research for non-alcoholic steatohepatitis biomarkers will continue supporting the growth of the market during the forecast period

Increasing research activities to raise the already available biomarkers' productivity and efficiency or discover new ones is expected to create enormous opportunities for growth in the non-alcoholic steatohepatitis market. The prevalence of non-alcoholic steatohepatitis across the globe is increasing dramatically, driving the requirement for various diagnosis methods. The current method for the diagnosis of non-alcoholic steatohepatitis includes live biopsy, which is an invasive procedure. Although liver biopsy is still considered the most reliable standard for diagnosing non-alcoholic steatohepatitis, it can lead to various clinical complications such as trauma and bleeding.

Also, government support through programs and initiatives is driving the growth of the global market. Organizations' increasing number of programs and initiatives to develop non-alcoholic steatohepatitis drugs and diagnostic tools significantly drives the market's growth. For instance, in 2021, Global liver institute released U.S. NASH action plan. This plan included updated guidelines for standards of care and coordinated care pathways, adoption and reimbursement of non-invasive diagnostics, Payor and health system research on patient-centric value-based care and benefit design and Integration of NASH into public health, regulatory, and legislative priorities.

Market Segmentation: The diagnostic tests segment accounted for the highest share in global non-alcoholic steatohepatitis therapeutics and diagnostics market

Only a few diagnostic tests are available to diagnose non-alcoholic steatohepatitis, including liver function tests, lipid profile tests, and fibrosis assessment tests. The presence of non-alcoholic steatohepatitis is confirmed when the diagnostic results of the tissue show fat, inflammation, and damage to liver cells. Moreover, several in-vitro diagnostics tests set to be released in 2021 will support segmental growth worldwide. Therefore, diagnostic tests contribute a major share in the growth of the global non-alcoholic steatohepatitis therapeutics and diagnostics market.

Based on the therapeutics, the non-alcoholic steatohepatitis therapeutics and diagnostics market has been classified into Ocaliva, Elafibranor, Cenicriviroc, Selonsertib, and others. Moreover, the Selonsertib segment held a significant share of market growth. Selonsertib for patients with linking fibrosis or compensated cirrhosis due to non-alcoholic steatohepatitis. It is an oral inhibitor of apoptosis signal-regulating kinase 1 (ASK1), likely anti-inflammatory, antineoplastic, and anti-fibrotic activities. Selonsertib targets and ties to the catalytic kinase domain of ASK1 in an ATP-competitive approach; by this means, preventing its phosphorylation and activation. Therefore, Selonsertib contributes a considerable share to the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market across the globe.

Geographical Penetration: North America is the dominating region during the forecast period

North America dominated the global non-alcoholic steatohepatitis therapeutics and diagnostics market and is expected to retain its position during the forecast period. The US contributed the largest share in the North American non-alcoholic steatohepatitis therapeutics and diagnostics market in the forecast period. The primary factor contributing to the market's growth includes the significant funding provided by government organizations and pharmaceutical companies for the R&D of biomarkers. The presence of sophisticated healthcare amenities and the growing incidence of diabetes, obesity, and fatty liver disease support this region's target market's growth.

The Asia Pacific is estimated to grow at a considerable growth rate in the non-alcoholic steatohepatitis therapeutics and diagnostics market during the forecast period. The growth of Asia-Pacific is mainly attributed to the rapidly evolving healthcare infrastructure and increasing awareness of chronic liver conditions. Moreover, the expansion of foreign market players in the nation's emerging economies, such as China and India.

Competitive Landscape:

The non-alcoholic steatohepatitis therapeutics and diagnostics market is highly competitive. The key non-alcoholic steatohepatitis therapeutics and diagnostics players contributing to the global market's growth include Abbvie Inc., Cadila Healthcare Limited, Genfit SA, Gilead Sciences Inc., Novo Nordisk A/S, Quest Diagnostics, Shire Plc, Siemens Healthineers, Thermo Fisher Scientific Inc. The major players are adopting new product launches and expansion strategies for global growth in the non-alcoholic steatohepatitis therapeutics and diagnostics market. In February 2020, Meridian Bioscience signed a definitive agreement to acquired exalenz bioscience. The value of the acquisition of these two companies is around $49 million. By this acquisition, Meridian will be adding Exalenz's flagship BreathID Breath Test Systems, a urea breath test platform for detecting Helicobacter pylori, often associated with peptic ulcers and gastric ulcers cancer. BreathID furthers Meridian's strategy to be the leading provider of gastrointestinal diagnostic solutions. The platform offers patient-friendly, noninvasive sample collection and best-in-class sensitivity and specificity for adult and pediatric patients. Also, in December 2021, Thermo Fisher Scientific Inc. announced that it had completed its acquisition of PPD, Inc., a global provider of clinical research services to the biopharma and biotech industry, for $17.4 billion. PPD provided services to the biotech and biopharma industries.

COVID-19 Impact: Negative impact on the global non-alcoholic steatohepatitis therapeutics and diagnostics market

The COVID-19 pandemic has hampered the growth of the non-alcoholic steatohepatitis therapeutics and diagnostics market. Though the risk for the occurrence of COVID-19 is considerably high in patients suffering from non-alcoholic steatohepatitis, the new diagnosis and treatments have declined amidst the crisis. Moreover, the ongoing research in research institutes and other private organizations has been reduced due to a diversion in the R&D of the COVID-19 vaccine. Therefore, the demand for non-alcoholic steatohepatitis therapeutics and diagnostics is expected to decrease market value growth in 2020.

The global non-alcoholic steatohepatitis therapeutics and diagnostics market report would provide an access to approximately 76 market data tables, 60 figures and 170 pages

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Scope of the Market

2. Key Trends and Developments

3. Executive Summary

  • 3.1. Market Snippet by Diagnostics
  • 3.2. Market Snippet by Therapeutics
  • 3.3. Market Snippet by Sales Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market impacting factors
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
  • 4.2. Impact analysis

5. Industry Analysis

  • 5.1. Porter's five forces analysis
  • 5.2. Value chain analysis
  • 5.3. Patent Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives

7. By Diagnostics

  • 7.1. Introduction
    • 7.1.1. Market size analysis, and y-o-y growth analysis (%), By Diagnostics

Segment

    • 7.1.2. Market attractiveness index, By Diagnostics Segment
  • 7.2. Imaging Techniques *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 7.3. Diagnostic Tests
  • 7.4. Biopsy

8. By Therapeutics

  • 8.1. Introduction
    • 8.1.1. Market size analysis, and y-o-y growth analysis (%), By Therapeutics Segment
    • 8.1.2. Market attractiveness index, By Therapeutics Segment
  • 8.2. Ocaliva *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 8.3. Elafibranor
  • 8.4. Cenicriviroc
  • 8.5. Selonsertib
  • 8.6. Others

9. By Sales Channel

  • 9.1. Introduction
    • 9.1.1. Market size analysis, and y-o-y growth analysis (%), By Sales Channel Segment
    • 9.1.2. Market attractiveness index, By Sales Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 And Y-O-Y Growth Analysis (%), 2021-2029
  • 9.3. Online Channel
  • 9.4. Retail Channel

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key region-specific dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.2.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. South America
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.3.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.3.6.1. Brazil
      • 10.3.6.2. Argentina
      • 10.3.6.3. Rest of South America
  • 10.4. Europe
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.4.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.4.6.1. Germany
      • 10.4.6.2. U.K.
      • 10.4.6.3. France
      • 10.4.6.4. Spain
      • 10.4.6.5. Italy
      • 10.4.6.6. Rest of Europe
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel
    • 10.5.6. Market Size Analysis, And Y-O-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Diagnostics
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapeutics
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sales Channel

11. Competitive Landscape

  • 11.1. Competitive scenario
  • 11.2. Competitor strategy analysis
  • 11.3. Market positioning/share analysis
  • 11.4. Mergers and acquisitions analysis

12. Company Profiles

  • 12.1. Abbvie Inc. *
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Cadila Healthcare Limited
  • 12.3. Conatus Pharmaceuticals Inc.
  • 12.4. Exalenz Bioscience Ltd.
  • 12.5. Genfit SA
  • 12.6. Gilead Sciences Inc.
  • 12.7. Intercept Pharmaceuticals Inc.
  • 12.8. Merck & Co., Inc.
  • 12.9. Novartis AG
  • 12.10. Novo Nordisk A/S
  • 12.11. Quest Diagnostics
  • 12.12. Shire Plc
  • 12.13. Siemens Healthineers
  • 12.14. Thermo Fisher Scientific Inc.
  • 12.15. WuXi AppTec
  • List not Exhaustive*

13. DataM

  • 13.1. Appendix
  • 13.2. About us and services
  • 13.3. Contact us